poisar

Stocks · News reference

Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10

Benzinga Newsdesk

Jefferies analyst Biren Amin upgrades Minerva Neurosciences (NASDAQ:NERV) from Hold to Buy and raises the price target from $7.5 to $10.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NERV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

    Minerva Neurosciences announced participation in two upcoming investor conferences (Wells Fargo Healthcare Conference on September 8 and Cantor Global Healthcare Conference on September 9, 2026). The company is conducting a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline efficacy data expected in the second half of 2027. The company has also established a Scientific Advisory Board of leading experts in psychiatry and neuroscience.

    NERV